Sanguine Corporation Presents a Message to Its Shareholders

PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC) presents a message to its shareholders: Dr Drees, Chairman and CEO of Sanguine stated, “Dear Sanguine Shareholders, let me take this opportunity to bring you current on the many programs that we have been working on during this last year. It has been a very important time for our company. Below you will find a brief overview on the product, PHER-O2, a synthetic red blood cell substitute and oxygen carrier; the current status for its FDA approval; significant changes to our management team; a direction moving our development stage company into a stronger and more diverse position; and what we see as a strong future for our shareholders.

Back to news